Anavex Life Sciences Corp (AVXL)

[xodcode]

Yes, conference call too. Never before have we AVXL shareholders witnessed such a confluence of potentially positive events at a point in time:

1. Vastly undervalued share price vis a vis competition.

2. Growing validation of AVXL approach to AD.

3. At same time loss of momentum in competitor's science for AD.

4. Relatively small share count.

5. A molecule whose properties are readily transferable to myriad CHS diseases.

6. A board and scientific advisory group of the best of the best.

7. Relatively small portion of institutional ownership. (about to significantly and positively change).

Exciting and prosperous times most certainly await current shareholders.